DDInter1544 DDInter546
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions . Dienogest is commonly marketed as Visanne, Natazia and Qlaira.
Dienogest {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cladribine
Dienogest {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Dienogest {u} may lead to a major life threatening interaction when taken with {v} Griseofulvin
Dienogest {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Cladribine
Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Dienogest may lead to a major life threatening interaction when taken with Griseofulvin
Dienogest may lead to a major life threatening interaction when taken with Encorafenib